(Q41435121)

30 September 2017

Scopolamine reverses haloperidol-attenuated lever-pressing for water but not haloperidol-attenuated water intake in the rat (English)

1 reference

https://api.crossref.org/works/10.1016/0091-3057(88)90298-5

30 December 2022

1 reference

https://api.crossref.org/works/10.1016/0091-3057(88)90298-5

30 December 2022

1 reference

https://api.crossref.org/works/10.1016/0091-3057(88)90298-5

30 December 2022

author name string

T. Ljungberg

1

1 reference

PubMed ID

3353427

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A3353427

30 December 2022

language of work or name

English

0 references

publication date

1 January 1988

1 reference

PubMed ID

3353427

full work available at URL

30 September 2017

https://api.elsevier.com/content/article/PII:0091305788902985?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0091-3057(88)90298-5

https://api.elsevier.com/content/article/PII:0091305788902985?httpAccept=text/plain

30 December 2022

1 reference

https://api.crossref.org/works/10.1016/0091-3057(88)90298-5

Pharmacology, Biochemistry and Behavior

30 December 2022

published in

1 reference

30 September 2017

29

1 reference

30 September 2017

205-208

1 reference

30 September 2017

1

1 reference

Pharmacological Specificity of Conditioned Avoidance Response Inhibition in Rats: Inhibition by Neuroleptics and Correlation to Dopamine Receptor Blockade

30 September 2017

1

1 reference

https://api.crossref.org/works/10.1016/0091-3057(88)90298-5

Differential reversal by scopolamine and thip of the antistereotypic and cataleptic effects of neuroleptics

30 December 2022

2

1 reference

https://api.crossref.org/works/10.1016/0091-3057(88)90298-5

Differential reversal by scopolamine of effects of neuroleptics in rats. Relevance for evaluation of therapeutic and extrapyramidal side-effect potential

30 December 2022

3

1 reference

https://api.crossref.org/works/10.1016/0091-3057(88)90298-5

A comparison of atropine, benztropine and diphenhydramine on the reversal of haloperidol induced suppression of self-stimulation.

30 December 2022

6

1 reference

https://api.crossref.org/works/10.1016/0091-3057(88)90298-5

Reversal of haloperidol induced deficits in self-stimulation by anti-Parkinsonian drugs

30 December 2022

7

1 reference

https://api.crossref.org/works/10.1016/0091-3057(88)90298-5

Drug-Induced Extrapyramidal Symptoms and Their Relations to Clinical Efficacy

30 December 2022

8

1 reference

https://api.crossref.org/works/10.1016/0091-3057(88)90298-5

Decreased antistereotypic effect of neuroleptics after additional treatment with a benzodiazepine, a GABA agonist or an anticholinergic compound

30 December 2022

9

1 reference

https://api.crossref.org/works/10.1016/0091-3057(88)90298-5

Haloperidol-induced disruption of conditioned avoidance responding: Attenuation by prior training or by anticholinergic drugs

30 December 2022

11

1 reference

https://api.crossref.org/works/10.1016/0091-3057(88)90298-5

Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data?

30 December 2022

13

1 reference

https://api.crossref.org/works/10.1016/0091-3057(88)90298-5

The interaction of neuroleptic and muscarinic agents with central dopaminergic systems

30 December 2022

14

1 reference

https://api.crossref.org/works/10.1016/0091-3057(88)90298-5

Blockade by neuroleptics of water intake and operant responding for water in the rat: anhedonia, motor deficit, or both?

30 December 2022

15

1 reference

https://api.crossref.org/works/10.1016/0091-3057(88)90298-5

Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing: Evidence for two different mechanisms of action

30 December 2022

17

1 reference

https://api.crossref.org/works/10.1016/0091-3057(88)90298-5

Evidence that the different properties of haloperidol and clozapine are not explained by differences in anticholinergic potency

30 December 2022

18

1 reference

https://api.crossref.org/works/10.1016/0091-3057(88)90298-5

A rapid and simple behavioural screening method for simultaneous assessment of limbic and striatal blocking effects of neuroleptic drugs.

30 December 2022

19

1 reference

https://api.crossref.org/works/10.1016/0091-3057(88)90298-5

Effects of antiparkinson drugs on a phenothiazine-induced catatonic reaction

30 December 2022

20

1 reference

https://api.crossref.org/works/10.1016/0091-3057(88)90298-5

Influence of antiparkinson drugs and amphetamine on some pharmacological effects of Phenothiazine derivatives used as neuroleptics

30 December 2022

21

1 reference

https://api.crossref.org/works/10.1016/0091-3057(88)90298-5

Neuroleptics: relation between cataleptic and anti-turning actions, and role of the cholinergic system.

30 December 2022

22

1 reference

https://api.crossref.org/works/10.1016/0091-3057(88)90298-5

Alterations by centrally acting drugs of the suppression of self-stimulation behavior in the rat by tetrabenazine, physostigmine, chlorpromazine and pentobarbital

30 December 2022

23

1 reference

https://api.crossref.org/works/10.1016/0091-3057(88)90298-5

Pharmacological properties of new antipsychotic agents: use of animal models

30 December 2022

24

1 reference

https://api.crossref.org/works/10.1016/0091-3057(88)90298-5

Differential attenuation of some effects of haloperidol in rats given scopolamine

30 December 2022

27

1 reference

https://api.crossref.org/works/10.1016/0091-3057(88)90298-5

Predictability and specificity of behavioral screening tests for nucleoleptics

30 December 2022

31

1 reference

https://api.crossref.org/works/10.1016/0091-3057(88)90298-5

30 December 2022

Identifiers

1 reference

30 September 2017

1 reference

PubMed ID

3353427